On Friday, Shares of Halliburton Company (NYSE:HAL), gained 0.05% to $41.33.
Halliburton Company, and Baker Hughes Incorporated (BHI) declared that they have reached a timing agreement with the Antitrust Division of the U.S. Department of Justice (DOJ) pursuant to which both companies have agreed to extend the period for the DOJ’s review of Halliburton’s formerly declared acquisition of Baker Hughes to the later of November 25, 2015 or 90 days after both companies have certified substantial compliance with the DOJ’s second request. Both Halliburton and Baker Hughes expect to certify substantial compliance with the DOJ’s second requests, issued to each company, by mid-summer. Timing agreements are often reached in connection with large, complex transactions, and provide the DOJ additional time to review responses to its second requests. In light of the timing agreement, Halliburton and Baker Hughes also have agreed to extend the time period for closing of the acquisition to no later than December 1, 2015.
Halliburton and Baker Hughes continue to be in discussions with the DOJ, the European Commission and other competition enforcement authorities with respect to the acquisition. As formerly declared, Halliburton is presently marketing for sale its Fixed Cutter and Roller Cone Drill Bits, Directional Drilling and Logging-While-Drilling (LWD)/Measurement-While-Drilling (MWD) businesses. In addition, Halliburton has shared with various competition enforcement authorities around the world a proposal to divest additional businesses of the companies which, together with the formerly declared divestitures, are within the scope of those contemplated by Halliburton at the time of the transaction. There is no agreement to date with any competition enforcement authority as to the adequacy of Halliburton’s proposal or any alternative proposal. The parties will continue to work constructively with all competition enforcement authorities that have expressed an interest in the projected transaction.
Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company operates through two segments, Completion and Production, and Drilling and Evaluation.
Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA), declined -1.21% to $61.38, during its last trading session.
Teva Pharmaceutical Industries Limited, declared the launch of generic Aggrenox® (aspirin/extended-release dipyridamole) capsules in the United States. Aspirin and extended-release dipyridamole capsules are used to lower the risk of stroke in people who have had a mini-stroke (transient ischemic attack or TIA) or stroke due to a blood clot.
A stroke is caused when there is an interruption to the flow of oxygen rich blood to the brain. Without oxygen, brain cells can become damaged and die. Sudden bleeding in the brain can also cause a stroke if it damages brain cells. A stroke can result in brain damage, long-term disability, or even death.
On average, one American dies from stroke every four minutes. As the fifth leading cause of death in America, every year, more than 795,000 people have a stroke, and 25% have had a previous stroke. About 130,000 people will die as the result of a stroke each year.
Aggrenox® (aspirin/extended-release dipyridamole) capsules had annual sales of about $457 million in the United States, according to IMS data as of April 2015.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients.
Finally, Qiagen NV (NASDAQ:QGEN), ended its last trade with 4.04% gain, and closed at $25.73.
Seegene, declared that it has reached a worldwide partnership agreement with QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt Prime Standard: QIA) to develop and supply molecular diagnostic assays.
Under the terms of the agreement, Seegene will develop and manufacture multiplex infectious disease testing panels exclusively designed for QIAGEN’s real-time PCR cycler Rotor-Gene Q, member of QIAGEN’s QIAsymphony family of automated instruments, and QIAGEN will have worldwide commercialization rights to these tests.
QIAGEN N.V. provides sample to insight solutions that transform biological samples into valuable molecular insights worldwide. It offers sample technologies to isolate, purify, and stabilize nucleic acids and proteins in plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technologies to detect molecular targets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
